FDA Sends Sutent sNDA For Pancreatic Cancer To ODAC

Oncologic Drugs Advisory Committee's April 12 review may have been spurred by any number of issues in the Phase III trial, including its early termination, reliability of progression-free survival assessments and failure to show quality-of-life improvements.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet